Daiichi Sankyo, Inc. (Daiichi)

Oncology Corporate Profile

HQ Location

Two Hilton Court
Parsippany, NJ 7054

Company Description

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies.

Website: http://dsi.com/

Brand Generic Indication
Zelboraf_?vemurafenibZELBORAF_? is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAFV600E mutation as detected by an FDA-approved test.

Limitation of Use: ZELBORAF is not recommended for use in patients with

wild-type BRAF melanoma.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
tivantinib / ARQ 197c-Met kinase inhibitorHepatocellular carcinoma (HCC)IIIArQule
Xgeva_ / denosumab / AMG 162anti-RANKL antibodyAdjuvant Breast cancerIIIAmgen (DSI rights in Japan)
tigatuzumab / CS-1008anti-DR5 antibody1st line metastatic Non Small Cell Lung Cancer (NSCLC)II
quizartinib / AC220Flt-3 kinase inhibitor2nd line metastatic Acute Myelogenous Leukemia (AML)IIAstellas
PLX3397Fms/Kit/Flt3-ITD inhibitorAcute Myelogenous Leukemia (AML)II
patritumabanti-HER3 antibodyBreast cancerII
tigatuzumab / CS-1008anti-DR5 antibodyColorectal cancerII
tivantinib (+ irinotecan/cetuximab) / ARQ 197c-Met kinase inhibitorColorectal cancerIIArQule
PLX3397Fms/Kit/Flt3-ITD inhibitorGlioblastoma Multiforme (GBM)IINULl
nimotuzumab / DE-766anti-EGFR monoclonal antibody (humanized)GliomaII
PLX3397Fms/Kit/Flt3-ITD inhibitorHodgkin's LymphomaII
patritumabanti-HER3 antibodyNon Small Cell Lung Cancer (NSCLC)II
efatutazone / CS-7017PPAR? agonistNon Small Cell Lung Cancer (NSCLC)II
tigatuzumab / CS-1008anti-DR5 antibodyOvarian cancerII
tigatuzumab / CS-1008anti-DR5 antibodyPancreatic cancerII
Zelboraf_ / vemurafenib / PLX4032Fms/Kit/Flt3 inhibitorColorectal cancerII
Zelboraf_ / vemurafenib / PLX4032 (+ PLX3397)Fms/Kit/Flt3 inhibitorMelanomaII
quizartinib (+ chemotherapy) / AC220Flt-3 kinase inhibitor1st line metastatic Acute Myelogenous Leukemia (AML)IAstellas
quizartinib / AC220Flt-3 kinase inhibitorAcute Myelogenous Leukemia (AML)IAstellas
U3-1287anti-HER3 antibodyBreast cancerI
DS-8201HER2-targeting antibody drug conjugateBreast cancerI
DS-8201HER2-targeting antibody drug conjugateGastric cancerI
PLX7486 (+ gemcitabine and nab-paclitaxel)Fms/Kit/Flt3 inhibitorPancreatic cancerI
efatutazone / CS-7017PPAR? agonistVarious cancer typesI
DS-7423PI3K/mTOR inhibitorVarious cancer typesI
DS-2248Hsp90 inhibitorVarious cancer typesI
DS-8273anti-DR5 antibodyVarious cancer typesI
U3-1565anti-HB-EGF antibodyVarious cancer typesI
DS-3078mTOR inhibitorVarious cancer typesI
DS-3032MDM2 inhibitorVarious cancer typesI
PLX7486Fms/Kit/Flt3 inhibitorVarious cancer typesI
U3-1287 (+ erlotinib) anti-HER3 antibody2nd line metastatic Non Small Cell Lung Cancer (NSCLC)II
AC708CSF1R inhibitorVarious cancer typesPreclinical
AC855CSF1R inhibitorVarious cancer typesPreclinical
CEP-32496BRAF kinase inhibitorVarious cancer typesPreclinicalTeva

View additional information on product candidates here »



Recent News Headlines

There are no news items to display